Managing Hypercapnia in a Coronavirus Disease 2019 Acute Respiratory Distress Syndrome with Extracorporeal Carbon Dioxide Removal Using Continuous Renal Replacement Therapy Machine: A Case Report
Citation Information :
Gupta V, Mohan B, Grover S, Kaur G, Wander GS. Managing Hypercapnia in a Coronavirus Disease 2019 Acute Respiratory Distress Syndrome with Extracorporeal Carbon Dioxide Removal Using Continuous Renal Replacement Therapy Machine: A Case Report. Indian J ECMO 2023; 1 (2):76-78.
Coronavirus disease-2019 (COVID-19) acute respiratory distress syndrome (ARDS) management remains challenging for intensivists, especially during limited resource availability. We report a COVID-19 ARDS case who had hypercapnia in spite of appropriate ventilatory management. This case was successfully managed with the use of extracorporeal carbon dioxide removal (ECCO2R) device with attaching pediatric oxygenator with continuous renal replacement therapy (CRRT).
Cardinal–Fernández P, Lorente JA, Ballén–Barragán A, et al. Acute respiratory distress syndrome and diffuse alveolar damage. New insights on a complex relationship. Ann Am Thorac Soc 2017;14(6):844–850. DOI: 10.1513/AnnalsATS.201609-728PS.
Burnham EL, Janssen WJ, Riches DWH, et al. The fibroproliferative response in acute respiratory distress syndrome: Mechanisms and clinical significance. EurRespir J 2014;43(1):276–285. DOI: 10.1183/09031936.00196412.
George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med 2020;8(8):807–815. DOI: 10.1016/S2213-2600(20)30225-3.
Thille AW, Esteban A, Fernández–Segoviano P, et al. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: A prospective cohort study of clinical autopsies. Lancet Respir Med 2013;1:395–401. DOI: 10.1016/S2213-2600(13)70053-5.
Fanelli V, Ranieri MV, Mancebo J, et al. Feasibility and safety of low-flow extracorporeal carbon dioxide removal to facilitate ultra-protective ventilation in patients with moderate acute respiratory distress syndrome. Crit Care 2016;20:36. DOI: 10.1186/s13054-016-1211-y.
Parrilla F, Bergesio L, Aguirre–Bermeo H, et al. Ultra-low tidal volumes and extracorporeal carbon dioxide removal (Hemolung® RAS) In ARDS patients: A clinical feasibility study. Intensive Care Med Exp 2015;3(Suppl. 1):A7. DOI: 10.1186/2197-425X-3-S1-A7.
Kalbhenn J, Neuffer N, Zieger B, et al. Is extracorporeal CO2 removal really “safe” and “less” invasive? Observation of blood injury and coagulation impairment during ECCO2R. ASAIO J Am Soc Artif Intern Organs 2017;63:666–671. DOI: 10.1097/MAT.0000000000000544.
Moss CE, Galtrey EJ, Camporota L, et al. A retrospective observational case series of low flow veno-venous extracorporeal carbon dioxide removal use in patients with respiratory failure. ASAIO J 2016;62(4):458–462. DOI: 10.1097/MAT.0000000000000386.
Combes A, Fanelli V, Pham T, et al. Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: The SUPERNOVA study. Intensive Care Med 2019;45(5):592–600. DOI: 10.1007/s00134-019-05567-4.
